TCGA-DK-A1AE-01A-11R-A13Y-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 16.13009198
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- E2F_TARGETS+0.570
- MYC_TARGETS_V1+0.550
- G2M_CHECKPOINT+0.530
- MTORC1_SIGNALING+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
- OXIDATIVE_PHOSPHORYLATION+0.260
- SPERMATOGENESIS+0.210
- UNFOLDED_PROTEIN_RESPONSE+0.200
- WNT_BETA_CATENIN_SIGNALING+0.190
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.400
- COAGULATION-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- TNFA_SIGNALING_VIA_NFKB-0.330
- APICAL_JUNCTION-0.320
- INFLAMMATORY_RESPONSE-0.290
- INTERFERON_ALPHA_RESPONSE-0.260
- INTERFERON_GAMMA_RESPONSE-0.260
- TGF_BETA_SIGNALING-0.250
- COMPLEMENT-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.894 |
| 2 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.892 |
| 3 | TCGA-77-7139-01A-11R-2045-07 | — | cohortSQ2 | 0.891 |
| 4 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.888 |
| 5 | SRR1313140 | — | E | 0.887 |
| 6 | TCGA-QK-A6VB-01A-12R-A34R-07 | — | — | 0.879 |
| 7 | ERR2208894 | — | — | 0.878 |
| 8 | 20090275.TNBC | — | E | 0.874 |
| 9 | 176e93be-1ae5-43f2-a0b5-17f31695e679 | — | — | 0.873 |
| 10 | C3L-01285 | — | cohortSQ2 | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.010 | Inavolisib | — uncovered |